查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球数位病理学市场（按产品、类型、应用、最终用户和地区划分）- 预测至 2030 年
市场调查报告书
商品编码
1745106

全球数位病理学市场（按产品、类型、应用、最终用户和地区划分）- 预测至 2030 年

Digital Pathology Market by Product (Scanner, Software, Storage System), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma & Biotech, Academia, Hospitals) - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 283 Pages | 订单完成后即时交付

价格

数位病理学测试市场规模依类型分为三类：扫描器、储存系统和软体。

鑑于这些仪器在数位病理学工作流程中的重要性，扫描仪预计将在2024年占据产品类型的最大份额。扫描仪对于病理学家在电脑萤幕上查看和分析组织样本至关重要，因为它可以将实体载玻片转换为高解析度的数位影像。远端诊断存取的发展对于提高病理学服务的可及性和效率至关重要，因为它允许病理学家无论身在何处都能评估病例，从而增加对扫描仪的需求。扫描仪技术的进步，例如扫描速度的提高和高解析度成像，正在改善工作流程、提高诊断准确性，并提升实验室和医疗机构的投资价值。

研究范围
调查年份 2024-2030
基准年 2024
预测期 2024-2030
对价单位 金额（十亿美元）
部分 按产品、按类型、按应用、按最终用户、按地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

这主要是由于癌症、心血管疾病和感染疾病等复杂慢性疾病的全球负担日益加重，这些疾病需要及时且准确的诊断结果。

数位病理检查、检测和诊断通常在显微镜接目镜下进行，具有多种优势，例如可以产生高解析度影像、提供自动分析、影像存檔、云端储存、远端病理幻灯片共用服务等。同样重要的是，它还具有能够跨机构提供协作咨询和协调、远端咨询（包括专家的第二意见）的独特优势。

此外，数位病理学正在迅速被采用和发展，融合了人工智慧 (AI)、机器学习 (ML) 和深度学习影像识别等现代技术，所有这些都有助于提高诊断准确性、缩短週转时间，甚至识别细微的组织学模式，使数位病理学成为世界各地实验室和医院临床实践的基本组成部分。

2024年，北美凭藉其成熟的医疗保健体系和对先进医疗技术的大量资金投入，引领了数位病理学市场。北美（尤其是美国和加拿大）的法规环境，为新兴数位病理学技术提供了相对较快的核准流程。此外，医疗服务提供者的认知度不断提升，以及对先进诊断解决方案的需求不断增长，这些因素共同推动了全部区域数位病理学的蓬勃发展。

本报告研究了全球数位病理学测试市场，并对市场按产品、类型、应用、最终用户、区域趋势和公司概况进行了详细分析。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章重要考察

第五章市场概述

  • 介绍
  • 市场动态
  • 产业趋势
  • 技术分析
  • 定价分析
  • 价值链分析
  • 生态系分析
  • 波特五力分析
  • HS 编码
  • 监管状况
  • 专利分析
  • 案例研究分析
  • 2025-2026 年重要会议与活动
  • 主要相关人员和采购标准
  • 最终用户分析
  • 经营模式分析
  • 投资金筹措场景
  • 人工智慧如何影响数位病理市场
  • 美国关税对数位病理学市场的影响
  • 价格影响分析
  • 对国家的影响

第六章数位病理学测试市场（按产品）

  • 介绍
  • 扫描器
  • 软体
  • 软体（按实施模型）
  • 储存系统

第七章数位病理学测试市场（按类型）

  • 介绍
  • 人类
  • 动物

第八章 数位病理学测试市场（按应用）

  • 介绍
  • 药物研发
  • 疾病诊断
  • 培训和教育

第九章数位病理学市场（按最终用户）

  • 介绍
  • 製药和生物技术公司
  • 医院和检测设施
  • 学术研究所
  • 诊断实验室
  • 兽医研究所

第 10 章数位病理学检测市场（按地区）

  • 介绍
  • 北美洲
    • 北美：宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲：宏观经济展望
    • 德国
    • 英国
    • 瑞典
    • 法国
    • 西班牙
    • 义大利
    • 其他的
  • 亚太地区
    • 亚太地区：宏观经济展望
    • 中国
    • 日本
    • 印度
    • 其他的
  • 拉丁美洲
    • 拉丁美洲：宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 改善医疗基础设施以支持市场成长
    • 中东和非洲宏观经济展望
    • 海湾合作委员会国家
    • 其他的

第十一章竞争格局

  • 概述
  • 主要参与企业的策略/优势
  • 收益分析
  • 市场占有率分析
  • 公司估值矩阵：2023 年主要参与企业
  • 公司估值矩阵：Start-Ups/中小企业，2023 年
  • 估值和财务指标
  • 品牌/软体比较分析
  • 竞争场景

第十二章 公司简介

  • 主要参与企业
    • DANAHER CORPORATION
    • HOFFMANN-LA ROCHE LTD.
    • SECTRA AB
    • HAMAMATSU PHOTONICS KK
    • KONINKLIJKE PHILIPS NV
    • AKOYA BIOSCIENCES, INC.
    • FUJIFILM HOLDINGS CORPORATION
    • HOLOGIC, INC.
    • 3DHISTECH LTD.
    • APOLLO ENTERPRISE IMAGING CORP.
    • XIFIN, INC.
    • HURON DIGITAL PATHOLOGY
    • INDICA LABS
    • OPTRASCAN, INC.
    • GLENCOE SOFTWARE, INC.
    • AIFORIA TECHNOLOGIES OY
    • PAIGE AI, INC.
    • PROSCIA, INC.
  • 其他公司
    • QUEST DIAGNOSTICS
    • KONFOONG BIOTECH INTERNATIONAL CO., LTD.
    • MIKROSCAN TECHNOLOGIES, INC.
    • MOTIC DIGITAL PATHOLOGY
    • KANTERON SYSTEMS
    • MORPHLE LABS INC.
    • EW HEALTHCARE PARTNERS

第十三章 附录

Product Code: HIT 2608

The market for digital pathology is segmented into three categories based on type: scanners, storage systems, and software. Given the significance of these devices in the digital pathology workflow, the scanners segment accounted for the largest share of the product category in 2024. Scanners are critical in enabling pathologists to view and analyze tissue samples on computer screens, as scanners convert physical glass slides to high-resolution digital images. The development of diagnostic remote access is paramount for improved accessibility and efficiency of pathology services by allowing pathologists to evaluate cases from any physical location, hence, the demand for scanners. The advancements in scanner technology, such as improved scanning rates and greater resolution imaging, have led to increased workflow, improved diagnostic accuracy, and value for investment for laboratories or medical facilities.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsProduct, Type, Application, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

By type, the human pathology segment is expected to hold the largest share during the forecast period.

The human pathology segment is expected to occupy the largest share of the digital pathology market throughout the forecast period largely due to the rising global burden of complex and chronic diseases, including cancer, cardiovascular diseases, and infections, which demand timely and accurate diagnostic outcomes.

Digital pathology, examination, and diagnosis, typically performed under the eyepiece of a microscope, are advantageous in many aspects, such as producing high-resolution images, providing automated analytics, allowing for image storage, cloud storage, and telepathology slide-sharing services. Equally important is the unparalleled advantage of being able to provide remote consultation that may involve co-consultation and coordination at various sites and second opinions from specialists.

Furthermore, digital pathology is quickly being adopted and evolving to integrate the newest technologies such as artificial intelligence (AI), machine learning (ML), deep learning image recognition, which are all improving diagnostic accuracy, decreasing turnaround time, and even aiding in recognizing subtle histological patterns, which makes digital pathology a foundational element of practice in laboratories and hospitals around the world.

North America is expected to lead the global digital pathology market during the forecast period.

North America led the digital pathology market in 2024 due to a mature healthcare system and large financial investments toward developing healthcare technology. The regulatory environment in North America-especially in the US and Canada-supports a relatively faster review and approval process for emerging digital pathology technologies. This, combined with growing awareness among healthcare providers and rising demand for advanced diagnostic solutions, has driven strong adoption of digital pathology across the region.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
  • By Designation: C-level (35%), Director-level (25%), and Others (40%)
  • By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and Middle East & Africa (5%)

List of Companies Profiled in the Report

Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Indica Labs Inc. (US), Objective Pathology Services Limited (Canada), Sectra AB (Sweden), OptraSCAN (US), Akoya Biosciences, Inc. (US), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Fujifilm Holdings Corporation (Japan), Proscia Inc. (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), and Kanteron Systems (Spain)

Research Coverage

This report studies the digital pathology market based on product, type, application, end user, and region. The report also analyses factors (such as drivers, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total digital pathology market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report

This report also includes.

  • Analysis of key drivers (Growing adoption of AI-enabled digital pathology, rising burden of cancer, diabetes, and chronic diseases, expansion of digital pathology in drug discovery and biomarker validation, Cancer screening programs in emerging markets), restraints (High initial capital costs, Data interoperability issues with existing lab systems, regulatory and reimbursement uncertainty), opportunities (Affordable scanner development for low-resource settings, growing preference for personalized medicine, government-backed digitization in emerging economies) challenges (Shortage of skilled pathologists and technicians, algorithm validation issues, data security and patient privacy concerns), are contributing the growth of the digital pathology market.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the digital pathology market
  • Market Development: Comprehensive information about lucrative markets and analysis of the authentication and brand protection market across varied regions
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the digital pathology market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global digital pathology market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 RESEARCH METHODOLOGY DESIGN
  • 2.3 MARKET SIZE ESTIMATION
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 MARKET ASSUMPTIONS
    • 2.6.1 OVERALL STUDY ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
  • 2.8 RESEARCH LIMITATIONS
    • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 DIGITAL PATHOLOGY MARKET OVERVIEW
  • 4.2 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER AND COUNTRY (2024)
  • 4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 DIGITAL PATHOLOGY MARKET: REGIONAL MIX

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 AI-enabled digital pathology improving lab throughput
      • 5.2.1.2 Rising burden of cancer, diabetes, and cardiovascular diseases
      • 5.2.1.3 Expansion of digital pathology in drug discovery and biomarker validation
      • 5.2.1.4 National cancer screening programs in emerging markets
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High initial capital cost of digital pathology systems
      • 5.2.2.2 Data interoperability issues with existing lab systems
      • 5.2.2.3 Regulatory and reimbursement uncertainty
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Affordable scanner development for low-resource settings
      • 5.2.3.2 Personalized medicine driving precision diagnostics
      • 5.2.3.3 Government-backed digitalization in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of skilled pathologists and technicians
      • 5.2.4.2 Algorithm validation and trust in AI-based diagnostics
      • 5.2.4.3 Data security and privacy concerns
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 AI-POWERED DIAGNOSTICS GO MAINSTREAM
    • 5.3.2 CLOUD-BASED PLATFORMS AND REMOTE ACCESS BECOME CRITICAL ENABLERS
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 CLOUD STORAGE & ARCHIVING
    • 5.4.2 WHOLE SLIDE IMAGING (WSI) SCANNERS
    • 5.4.3 IMAGE MANAGEMENT SYSTEMS
    • 5.4.4 ADJACENT TECHNOLOGIES
      • 5.4.4.1 Genomic sequencing
      • 5.4.4.2 Artificial Intelligence and Machine Learning
    • 5.4.5 COMPLEMENTARY TECHNOLOGIES
      • 5.4.5.1 LIS & PACS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION
    • 5.5.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 HS CODES
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 REGULATORY ANALYSIS
      • 5.10.2.1 North America
        • 5.10.2.1.1 US
        • 5.10.2.1.2 Canada
      • 5.10.2.2 Europe
      • 5.10.2.3 Asia Pacific
        • 5.10.2.3.1 Japan
        • 5.10.2.3.2 China
        • 5.10.2.3.3 India
  • 5.11 PATENT ANALYSIS
    • 5.11.1 PATENT PUBLICATION TRENDS
    • 5.11.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS
    • 5.11.3 MAJOR PATENTS
  • 5.12 CASE STUDY ANALYSIS
  • 5.13 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 BUYING CRITERIA
    • 5.14.3 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.15 END-USER ANALYSIS
    • 5.15.1 UNMET NEEDS
    • 5.15.2 END-USER EXPECTATIONS
  • 5.16 BUSINESS MODEL ANALYSIS
  • 5.17 INVESTMENT & FUNDING SCENARIO
  • 5.18 IMPACT OF AI ON DIGITAL PATHOLOGY MARKET
  • 5.19 IMPACT OF US TARIFF ON DIGITAL PATHOLOGY MARKET
    • 5.19.1 INTRODUCTION
    • 5.19.2 KEY TARIFF RATES
  • 5.20 PRICE IMPACT ANALYSIS
  • 5.21 IMPACT ON COUNTRY/REGION
    • 5.21.1 US
    • 5.21.2 EUROPE
    • 5.21.3 ASIA PACIFIC
    • 5.21.4 IMPACT ON END-USE INDUSTRIES

6 DIGITAL PATHOLOGY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 SCANNERS
    • 6.2.1 BRIGHTFIELD SCANNERS
      • 6.2.1.1 Cost-efficient features to boost demand
    • 6.2.2 FLUORESCENCE SCANNERS
      • 6.2.2.1 Ability to detect cellular structures and biomarkers to fuel uptake
    • 6.2.3 OTHER SCANNERS
  • 6.3 SOFTWARE
    • 6.3.1 INTEGRATED SOFTWARE
      • 6.3.1.1 Single & effective suite for multiple applications to propel market
    • 6.3.2 STANDALONE SOFTWARE
      • 6.3.2.1 Information management software
        • 6.3.2.1.1 Management of image repositories to fuel uptake
      • 6.3.2.2 Image analysis software
        • 6.3.2.2.1 Ability to automate quantitative evaluation to support market growth
  • 6.4 SOFTWARE, BY DEPLOYMENT MODEL
    • 6.4.1 CLOUD-BASED MODEL
      • 6.4.1.1 Facilitation of collaboration on a single platform to drive market
    • 6.4.2 ON-PREMISE MODEL
      • 6.4.2.1 High data security and integration with HCIT solutions to fuel uptake
    • 6.4.3 HYBRID MODEL
      • 6.4.3.1 Combined flexibility to support market growth
  • 6.5 STORAGE SYSTEMS
    • 6.5.1 GROWING FOCUS ON STORAGE OF HIGH-RESOLUTION IMAGES TO DRIVE MARKET

7 DIGITAL PATHOLOGY MARKET, BY TYPE

  • 7.1 INTRODUCTION
  • 7.2 HUMAN PATHOLOGY
    • 7.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO PROPEL MARKET
  • 7.3 VETERINARY PATHOLOGY
    • 7.3.1 IMPROVEMENTS IN ANIMAL DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH

8 DIGITAL PATHOLOGY MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 DRUG DISCOVERY
    • 8.2.1 INCREASING FOCUS ON LIFE SCIENCES R&D TO DRIVE MARKET
  • 8.3 DISEASE DIAGNOSIS
    • 8.3.1 INTEGRATION OF AI & ML IN COMPLEX DIAGNOSTICS TO BOOST DEMAND
  • 8.4 TRAINING & EDUCATION
    • 8.4.1 ABILITY TO PROVIDE REAL-TIME LEARNING EXPERIENCES TO SUPPORT MARKET GROWTH

9 DIGITAL PATHOLOGY MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 INCREASING FOCUS ON DRUG TOXICOLOGY TESTING AND RISING NUMBER OF PRECLINICAL TRIALS TO PROPEL MARKET
  • 9.3 HOSPITALS & REFERENCE LABORATORIES
    • 9.3.1 HIGH INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH
  • 9.5 DIAGNOSTICS LABORATORIES
    • 9.5.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH
  • 9.6 VETERINARY LABORATORIES
    • 9.6.1 TECHNOLOGICAL ADVANCEMENTS, PARTICULARLY IN WHOLE-SLIDE IMAGING SYSTEMS AND AI-POWERED IMAGE ANALYSIS SOFTWARE, SUPPORT MARKET GROWTH

10 DIGITAL PATHOLOGY MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
    • 10.2.2 US
      • 10.2.2.1 Favorable reimbursements for diagnostics to drive market
    • 10.2.3 CANADA
      • 10.2.3.1 Growing awareness on early cancer detection & diagnosis to drive market
  • 10.3 EUROPE
    • 10.3.1 EUROPE: MACROECONOMIC OUTLOOK
    • 10.3.2 GERMANY
      • 10.3.2.1 High healthcare expenditure and supportive research initiatives to drive market
    • 10.3.3 UK
      • 10.3.3.1 Government funding investments for pathology services to fuel market
    • 10.3.4 SWEDEN
      • 10.3.4.1 Increasing prevalence of chronic diseases to support market growth
    • 10.3.5 FRANCE
      • 10.3.5.1 Increasing government funding and favorable insurance system to drive adoption
    • 10.3.6 SPAIN
      • 10.3.6.1 Supportive collaborations among leading companies and hospitals to boost demand
    • 10.3.7 ITALY
      • 10.3.7.1 Integration of AI & ML to support market growth
    • 10.3.8 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
    • 10.4.2 CHINA
      • 10.4.2.1 Increasing establishment of hospitals and reference laboratories to drive market
    • 10.4.3 JAPAN
      • 10.4.3.1 Advanced healthcare infrastructure to support market growth
    • 10.4.4 INDIA
      • 10.4.4.1 Growth in pharmaceutical industry to propel market
    • 10.4.5 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
    • 10.5.2 BRAZIL
      • 10.5.2.1 High adoption of POC testing to drive market
    • 10.5.3 MEXICO
      • 10.5.3.1 Growth in companion diagnostics to fuel uptake
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 10.6.3 GCC COUNTRIES
    • 10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET
  • 11.3 REVENUE ANALYSIS
  • 11.4 MARKET SHARE ANALYSIS
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Product footprint
      • 11.5.5.3 Application footprint
      • 11.5.5.4 End-user footprint
      • 11.5.5.5 Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
  • 11.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.8 BRAND/SOFTWARE COMPARATIVE ANALYSIS
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
    • 11.9.2 DEALS
    • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY COMPANIES
    • 12.1.1 DANAHER CORPORATION
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Deals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Key strengths
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses and competitive threats
    • 12.1.2 HOFFMANN-LA ROCHE LTD.
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Product launches & approvals
        • 12.1.2.3.2 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Key strengths
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses and competitive threats
    • 12.1.3 SECTRA AB
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Deals
        • 12.1.3.3.2 Other developments
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Key strengths
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses and competitive threats
    • 12.1.4 HAMAMATSU PHOTONICS K.K.
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Product approvals
        • 12.1.4.3.2 Deals
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Key strengths
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses and competitive threats
    • 12.1.5 KONINKLIJKE PHILIPS N.V.
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Product launches & approvals
        • 12.1.5.3.2 Deals
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Key strengths
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses and competitive threats
    • 12.1.6 AKOYA BIOSCIENCES, INC.
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
      • 12.1.6.3 Recent developments
        • 12.1.6.3.1 Product launches & approvals
    • 12.1.7 FUJIFILM HOLDINGS CORPORATION
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Deals
    • 12.1.8 HOLOGIC, INC.
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Product approvals
    • 12.1.9 3DHISTECH LTD.
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Product launches & enhancements
        • 12.1.9.3.2 Other developments
    • 12.1.10 APOLLO ENTERPRISE IMAGING CORP.
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products offered
      • 12.1.10.3 Recent developments
        • 12.1.10.3.1 Product enhancements
        • 12.1.10.3.2 Deals
    • 12.1.11 XIFIN, INC.
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products offered
      • 12.1.11.3 Recent developments
        • 12.1.11.3.1 Product launches
        • 12.1.11.3.2 Deals
    • 12.1.12 HURON DIGITAL PATHOLOGY
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products offered
        • 12.1.12.2.1 Deals
    • 12.1.13 INDICA LABS
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products offered
      • 12.1.13.3 Recent developments
        • 12.1.13.3.1 Product launches & approvals
        • 12.1.13.3.2 Deals
    • 12.1.14 OPTRASCAN, INC.
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products offered
      • 12.1.14.3 Recent developments
        • 12.1.14.3.1 Product launches & approvals
        • 12.1.14.3.2 Deals
    • 12.1.15 GLENCOE SOFTWARE, INC.
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products offered
      • 12.1.15.3 Recent developments
        • 12.1.15.3.1 Product enhancements
    • 12.1.16 AIFORIA TECHNOLOGIES OY
      • 12.1.16.1 Business overview
      • 12.1.16.2 Products offered
      • 12.1.16.3 Recent developments
        • 12.1.16.3.1 Deals
    • 12.1.17 PAIGE AI, INC.
      • 12.1.17.1 Business overview
      • 12.1.17.2 Products offered
      • 12.1.17.3 Recent developments
        • 12.1.17.3.1 Product launches & enhancements
        • 12.1.17.3.2 Deals
    • 12.1.18 PROSCIA, INC.
      • 12.1.18.1 Business overview
      • 12.1.18.2 Products offered
      • 12.1.18.3 Recent developments
        • 12.1.18.3.1 Product enhancements & approvals
        • 12.1.18.3.2 Deals
  • 12.2 OTHER PLAYERS
    • 12.2.1 QUEST DIAGNOSTICS
    • 12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD.
    • 12.2.3 MIKROSCAN TECHNOLOGIES, INC.
    • 12.2.4 MOTIC DIGITAL PATHOLOGY
    • 12.2.5 KANTERON SYSTEMS
    • 12.2.6 MORPHLE LABS INC.
    • 12.2.7 EW HEALTHCARE PARTNERS

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 FACTOR ANALYSIS
  • TABLE 2 RISK ASSESSMENT ANALYSIS
  • TABLE 3 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
  • TABLE 4 AVERAGE SELLING PRICE TREND OF DIGITAL PATHOLOGY PRODUCTS, BY REGION
  • TABLE 5 AVERAGE SELLING PRICE OF DIGITAL PATHOLOGY PRODUCTS
  • TABLE 6 DIGITAL PATHOLOGY MARKET: PORTER'S FIVE FORCES
  • TABLE 7 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 10 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES
  • TABLE 12 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 13 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 14 LIST OF PATENTS/PATENT APPLICATIONS
  • TABLE 15 CASE STUDY 1: ASSESSING IMAGE QUALITY: A COMPARATIVE MULTI-ASSESSMENT EVALUATION OF APERIO GT 450 DX
  • TABLE 16 CASE STUDY 2: HOW TO PROMOTE PATHOLOGY WORKFLOW EFFICIENCY
  • TABLE 17 CASE STUDY 3: ARTIFICIAL INTELLIGENCE IN DIGITAL PATHOLOGY
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DIGITAL PATHOLOGY PRODUCTS
  • TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DIGITAL PATHOLOGY, BY PRODUCT
  • TABLE 20 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS
  • TABLE 21 UNMET NEEDS IN DIGITAL PATHOLOGY MARKET
  • TABLE 22 END-USER EXPECTATIONS IN DIGITAL PATHOLOGY MARKET
  • TABLE 23 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 24 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 25 SCANNING MAGNIFICATION AND APPLICATIONS
  • TABLE 26 DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS
  • TABLE 27 DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 28 DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 29 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS
  • TABLE 30 BRIGHTFIELD SCANNERS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 31 FLUORESCENCE SCANNERS OFFERED BY KEY MARKET PLAYERS
  • TABLE 32 FLUORESCENCE SCANNERS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 33 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS
  • TABLE 34 OTHER SCANNERS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 35 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 36 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 37 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 38 INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 39 INTEGRATED SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 40 STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 41 STANDALONE SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 42 INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 43 INFORMATION MANAGEMENT SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 44 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 45 IMAGE ANALYSIS SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 46 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 47 CLOUD-BASED SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 48 CLOUD-BASED MODEL MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 49 ON-PREMISE SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 50 ON-PREMISE MODEL MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 51 HYBRID SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 52 HYBRID MODEL MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 53 STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS
  • TABLE 54 DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 55 DIGITAL PATHOLOGY MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 56 HUMAN DIGITAL PATHOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 57 VETERINARY DIGITAL PATHOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 58 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 59 SOFTWARE IMPACT ANALYSIS, BY APPLICATION
  • TABLE 60 DIGITAL PATHOLOGY APPLICATIONS IN DRUG DISCOVERY
  • TABLE 61 DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 62 DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 63 DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 64 DIGITAL PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 65 DIGITAL PATHOLOGY MARKET: SOFTWARE IMPACT ANALYSIS, BY END USER
  • TABLE 66 DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 67 DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS, BY HOSPITAL
  • TABLE 68 DIGITAL PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 69 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 70 DIGITAL PATHOLOGY MARKET FOR DIAGNOSTICS LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 71 DIGITAL PATHOLOGY MARKET FOR VETERINARY LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 72 DIGITAL PATHOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 73 NORTH AMERICA: MACROECONOMIC OUTLOOK, 2024
  • TABLE 74 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 76 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 77 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 78 NORTH AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 79 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 80 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 81 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 82 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 83 US: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
  • TABLE 84 US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 85 US: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 86 US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 87 US: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 88 US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 89 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 90 CANADA: FUNDING INITIATIVES FOR DIGITAL PATHOLOGY
  • TABLE 91 CANADA: KEY MACROINDICATORS
  • TABLE 92 CANADA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 93 CANADA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 94 CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 95 CANADA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 96 CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 97 EUROPE: MACROECONOMIC OUTLOOK
  • TABLE 98 EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 100 EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 101 EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 102 EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 103 EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 104 EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 105 EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 106 EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 107 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 108 GERMANY: KEY MACROINDICATORS
  • TABLE 109 GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 110 GERMANY: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 111 GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 112 GERMANY: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 113 GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 114 UK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 115 UK: KEY MACROINDICATORS
  • TABLE 116 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 117 UK: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 118 UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 119 UK: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 120 UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 121 SWEDEN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 122 SWEDEN: KEY MACROINDICATORS
  • TABLE 123 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 124 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 125 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 126 SWEDEN: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 127 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 128 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 129 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 130 FRANCE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 131 FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 132 FRANCE: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 133 FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 134 SPAIN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 135 SPAIN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 136 SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 137 SPAIN: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 138 SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 139 ITALY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 140 ITALY: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 141 ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 142 ITALY: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 143 ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 144 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 145 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 146 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 147 REST OF EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 148 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: MACROINDICATORS
  • TABLE 150 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 152 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 154 ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 156 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 158 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 159 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 160 CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 161 CHINA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 162 CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 163 CHINA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 164 CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 165 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 166 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 167 JAPAN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 168 JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 169 JAPAN: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 170 JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 171 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 172 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 173 INDIA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 174 INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 175 INDIA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 176 INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 177 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 178 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 179 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 180 REST OF ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 181 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 182 LATIN AMERICA: MACROINDICATORS
  • TABLE 183 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 184 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 185 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 186 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 187 LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 188 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 189 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 190 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 191 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 192 BRAZIL: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 193 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 194 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 195 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 196 BRAZIL: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 197 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 198 MEXICO: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 199 MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 200 MEXICO: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 201 MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 202 MEXICO: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 203 MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 204 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 205 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 206 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 207 REST OF LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 208 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 209 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
  • TABLE 210 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 211 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 212 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 213 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 214 MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 215 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 216 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 217 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 218 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 219 GCC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 220 GCC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 221 GCC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 222 GCC: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 223 GCC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 224 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 225 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 226 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 227 REST OF MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 228 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023-2030 (USD MILLION)
  • TABLE 229 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 230 DIGITAL PATHOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 231 DIGITAL PATHOLOGY MARKET: PRODUCT FOOTPRINT
  • TABLE 232 DIGITAL PATHOLOGY MARKET: APPLICATION FOOTPRINT
  • TABLE 233 DIGITAL PATHOLOGY MARKET: END-USER FOOTPRINT
  • TABLE 234 DIGITAL PATHOLOGY MARKET: REGION FOOTPRINT
  • TABLE 235 DIGITAL PATHOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 236 DIGITAL PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 237 DIGITAL PATHOLOGY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 238 DIGITAL PATHOLOGY MARKET: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 239 DIGITAL PATHOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 240 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 241 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 242 DANAHER CORPORATION: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 243 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 244 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 245 HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 246 HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 247 SECTRA AB: COMPANY OVERVIEW
  • TABLE 248 SECTRA AB: PRODUCTS OFFERED
  • TABLE 249 SECTRA AB: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 250 SECTRA AB: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 251 HAMAMATSU PHOTONICS K.K.: COMPANY OVERVIEW
  • TABLE 252 HAMAMATSU PHOTONICS K.K.: PRODUCTS OFFERED
  • TABLE 253 HAMAMATSU PHOTONICS K.K.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 254 HAMAMATSU PHOTONICS K.K.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 255 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 256 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
  • TABLE 257 KONINKLIJKE PHILIPS N.V: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 258 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 259 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 260 AKOYA BIOSCIENCES INC.: PRODUCTS OFFERED
  • TABLE 261 AKOYA BIOSCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2024
  • TABLE 262 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 263 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED
  • TABLE 264 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 265 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 266 HOLOGIC, INC: PRODUCTS OFFERED
  • TABLE 267 HOLOGIC, INC: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 268 3DHISTECH LTD.: COMPANY OVERVIEW
  • TABLE 269 3DHISTECH LTD.: PRODUCTS OFFERED
  • TABLE 270 3DHISTECH LTD.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022-JUNE 2024
  • TABLE 271 3DHISTECH LTD.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2024
  • TABLE 272 APOLLO ENTERPRISE IMAGING CORP.: COMPANY OVERVIEW
  • TABLE 273 APOLLO ENTERPRISE IMAGING CORP.: PRODUCTS OFFERED
  • TABLE 274 APOLLO ENTERPRISE IMAGING CORP.: PRODUCT ENHANCEMENTS, JANUARY 2022-JUNE 2025
  • TABLE 275 APOLLO ENTERPRISE IMAGING CORP.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 276 XIFIN, INC.: COMPANY OVERVIEW
  • TABLE 277 XIFIN, INC.: PRODUCTS OFFERED
  • TABLE 278 XIFIN, INC.: PRODUCT LAUNCHES, JANUARY 2022-JUNE 2025
  • TABLE 279 XIFIN, INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 280 HURON DIGITAL PATHOLOGY: COMPANY OVERVIEW
  • TABLE 281 HURON DIGITAL PATHOLOGY: PRODUCTS OFFERED
  • TABLE 282 HURON DIGITAL PATHOLOGY: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 283 INDICA LABS: COMPANY OVERVIEW
  • TABLE 284 INDICA LABS: PRODUCTS OFFERED
  • TABLE 285 INDICA LABS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 286 INDICA LABS: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 287 OPTRASCAN, INC.: COMPANY OVERVIEW
  • TABLE 288 OPTRASCAN, INC.: PRODUCTS OFFERED
  • TABLE 289 OPTRASCAN, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 290 OPTRASCAN, INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 291 GLENCOE SOFTWARE, INC.: COMPANY OVERVIEW
  • TABLE 292 GLENCOE SOFTWARE, INC.: PRODUCTS OFFERED
  • TABLE 293 GLENCOE SOFTWARE, INC.: PRODUCT ENHANCEMENTS, JANUARY 2022-JUNE 2025
  • TABLE 294 AIFORIA TECHNOLOGIES OY: COMPANY OVERVIEW
  • TABLE 295 AIFORIA TECHNOLOGIES OY: PRODUCTS OFFERED
  • TABLE 296 PAIGE AI, INC.: COMPANY OVERVIEW
  • TABLE 297 PAIGE AI, INC.: PRODUCTS OFFERED
  • TABLE 298 PAIGE AI, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022-JUNE 2025
  • TABLE 299 PAIGE AI, INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 300 PROSCIA, INC.: COMPANY OVERVIEW
  • TABLE 301 PROSCIA, INC.: PRODUCTS OFFERED
  • TABLE 302 PROSCIA, INC.: PRODUCT ENHANCEMENTS & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 303 PROSCIA, INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 304 QUEST DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 305 KONFOONG BIOTECH INTERNATIONAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 306 MIKROSCAN TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 307 MOTIC DIGITAL PATHOLOGY: COMPANY OVERVIEW
  • TABLE 308 KANTERON SYSTEMS: COMPANY OVERVIEW
  • TABLE 309 MORPHLE LABS INC.: COMPANY OVERVIEW
  • TABLE 310 EW HEALTHCARE PARTNERS: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 DIGITAL PATHOLOGY MARKET
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 7 DIGITAL PATHOLOGY MARKET: REVENUE SHARE ANALYSIS OF DANAHER CORPORATION
  • FIGURE 8 BOTTOM-UP APPROACH
  • FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN DIGITAL PATHOLOGY MARKET (2025-2030)
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 DIGITAL PATHOLOGY MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 DIGITAL PATHOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 GEOGRAPHIC SNAPSHOT OF DIGITAL PATHOLOGY MARKET
  • FIGURE 17 RISING INCIDENCE OF CANCER AND GROWING ADOPTION OF PATHOLOGY SOLUTIONS FOR ENHANCED LAB EFFICIENCY TO DRIVE MARKET
  • FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
  • FIGURE 19 UK TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 20 ASIA PACIFIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 21 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 GLOBAL CANCER INCIDENCE, 2008-2030
  • FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015-2022
  • FIGURE 24 DIGITAL PATHOLOGY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 DIGITAL PATHOLOGY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 26 DIGITAL PATHOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 27 EUROPE: IVDR TIMELINE
  • FIGURE 28 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS, 2014-2025
  • FIGURE 29 MAJOR PATENTS FOR DIGITAL PATHOLOGY (2015-2025)
  • FIGURE 30 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS
  • FIGURE 31 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 32 RECENT FUNDING OF PLAYERS IN DIGITAL PATHOLOGY MARKET
  • FIGURE 33 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT
  • FIGURE 34 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET SNAPSHOT
  • FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL PATHOLOGY MARKET
  • FIGURE 36 DIGITAL PATHOLOGY MARKET SHARE ANALYSIS
  • FIGURE 37 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 38 DIGITAL PATHOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 39 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 40 EV/EBITDA OF KEY VENDORS
  • FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF DIGITAL PATHOLOGY VENDORS
  • FIGURE 42 DIGITAL PATHOLOGY MARKET: BRAND/SOFTWARE COMPARATIVE ANALYSIS
  • FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 45 SECTRA AB: COMPANY SNAPSHOT (2024)
  • FIGURE 46 HAMAMATSU PHOTONICS K.K.: COMPANY SNAPSHOT (2024)
  • FIGURE 47 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024)
  • FIGURE 48 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 49 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 50 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)